Skip to main content

International Congress on Neuromuscular Diseases (ICMND), 2026

Filter
Filter
⁨⁨⁨⁨Keyword (eg, author, condition)
Content type:
Clear filters
Quality of life in myasthenia gravis: Post hoc pooled analysis of Phase 3 rozanolixizumab studies
Jana Zschüntzsch, Ali A. Habib, Zabeen K. Mahuwala, et al.
Minimal symptom expression in myasthenia gravis: A post hoc analysis of Phase 3 rozanolixizumab studies
John Vissing, Ali A. Habib, Zabeen K. Mahuwala, et al.
Characterisation of patients with generalised myasthenia gravis on rozanolixizumab treatment in European Managed Access Programmes
Thaïs Tarancón, Paolo Emilio Alboini, Silvia Falso, et al.
Characterisation of patients with generalised myasthenia gravis on zilucoplan treatment in European Managed Access Programmes
Natasa Savic, Paolo Emilio Alboini, Pascal Cintas, et al.
Individual item-level analyses of myasthenia gravis-specific outcomes during zilucoplan treatment in RAISE and RAISE-XT
Channa Hewamadduma, Miriam Freimer, M. Isabel Leite, et al.
Myasthenia gravis during pregnancy: A descriptive real-world study based on US claims data
Sabrina Guye, Bright Dube, Jenny Lindroos, et al.
Effect of rozanolixizumab on MG-ADL and QMG items: A post hoc Phase 3 final pooled analysis
Laura Fionda, Elena Cortés Vicente, Artur Drużdż, et al.
Effect of rozanolixizumab on ocular symptoms in generalised myasthenia gravis: Analysis of Phase 3 studies
Elena Cortés Vicente, Ali A. Habib, Zabeen K. Mahuwala, et al.